CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814 · Phase 3 · Recruiting

PHASEPhase 3

STATUSRecruiting

ENROLLMENT744

EST. COMPLETION2026-09-30

Conditions

Metastatic Non-small Cell Lung Cancer

Interventions

Dato-DXdOsimertinibPemetrexedCarboplatinCisplatin

Study details

SPONSORAstraZeneca

START DATE2024-10-04

Related company profiles

AstraZeneca

AZN

Primary source

ClinicalTrials.gov record NCT06417814 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT06417814
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record